-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Today, AstraZeneca and Sanofi jointly announced that the research antibody nirsevimab has reached the primary endpoint in a phase 3 clinical trial, successfully preventing respiratory syncytial virus (RSV) infection in infants.
Respiratory syncytial virus is a very common infectious pathogen that can cause seasonal epidemics of lower respiratory tract infections (LRTI), including bronchiolitis and pneumonia.
Nirsevimab is a long-acting antibody, jointly developed by AstraZeneca and Sanofi, which can directly provide immunity to infants and provide immediate protection against RSV.
In the phase 3 clinical trial, nirsevimab reached the primary endpoint.
Note: This article aims to introduce the progress of medical and health research, not to recommend treatment options.